Current Findings in the Resistance Mechanism of Anti-CD19 CAR T-Cell Therapy in B-Cell Malignancies: A Literature Review
Indonesian Journal of Cancer · 30.06.2026 · 20 (2) · 318-327
DOI: 10.33371/ijoc.v20i2.1399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indonesian Journal of Cancer, online erschienen am 30.06.2026. Verfasst von Michelle Trisya und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy targeting CD19 on B-cells has emerged as a promising treatment for B-cell malignancies such as B-Acute Lymphoblastic Leukemia (B-ALL) and Diffuse Large B-cell Lymphoma (DLBCL). Despite its success, resistance mechanisms, including immune checkpoint inhibitors, persistent antigen stimulation, T-cell exhaustion, antigen loss, lineage switch, tumor heterogeneity, impaired death receptor signalling, and the tumor microenvironment, pose significant challenges. Understanding these mechanisms is crucial to advancing CAR T-cell therapy and improving its efficacy.
Methods
This literature review was conducted by analyzing peer-reviewed articles and clinical trials focusing on CAR T-cell therapy for B-ALL and DLBCL. Key mechanisms of resistance were identified, and their biological underpinnings were evaluated to highlight trends and potential strategies for overcoming resistance. Sources included PubMed, Science Direct, Google Scholar, and Google database using keywords such as ‘CD19,’ ‘CAR T-cell,’ ‘B-ALL,’ and ‘DLBCL’. Most articles were published within the past five years and were selected from journals with a high impact factor, and some older publications were included for foundational and theoretical insights.
Results
The review identifies multiple resistance mechanisms, including persistent antigen stimulation leading to T-cell exhaustion, immune checkpoint inhibitors suppressing effector functions, and tumor intrinsic factors like antigen loss and lineage switch. The role of the tumor microenvironment, with its immunosuppressive components, also contributes significantly to treatment failure. These findings underscore the complexity of resistance pathways and the need for combinatory and innovative approaches to enhance therapeutic outcomes.
Conclusions
Resistance to CAR T-cell therapy presents a significant challenge in treating B-cell malignancies. Addressing these mechanisms requires further research into combination therapies, multi-antigen targeting, and tumor microenvironment modulation. These strategies have the potential to optimize CAR T-cell efficacy and improve patient survival rates
Zitieren
APA
Trisya, M., & Karmanita, P. R. K. (2026). Current Findings in the Resistance Mechanism of Anti-CD19 CAR T-Cell Therapy in B-Cell Malignancies: A Literature Review. Indonesian Journal of Cancer, 20(2), 318-327. https://doi.org/10.33371/ijoc.v20i2.1399
Vancouver
Trisya M, Karmanita PRK. Current Findings in the Resistance Mechanism of Anti-CD19 CAR T-Cell Therapy in B-Cell Malignancies: A Literature Review. Indonesian Journal of Cancer. 2026;20(2):318-327. doi:10.33371/ijoc.v20i2.1399
BibTeX
@article{Trisya2026,
author = {Trisya, Michelle and Karmanita, Putu Radhya Kirana},
title = {Current Findings in the Resistance Mechanism of Anti-CD19 CAR T-Cell Therapy in B-Cell Malignancies: A Literature Review},
journal = {Indonesian Journal of Cancer},
year = {2026},
volume = {20},
number = {2},
pages = {318--327},
doi = {10.33371/ijoc.v20i2.1399}
}
EUVIMED